We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Study Evaluates Molecular Diagnostics Tests for SARS-CoV-2

By LabMedica International staff writers
Posted on 04 Jun 2020
Print article
Image: The Cepheid Xpert Xpress SARS-CoV-2 test was compared favorably with other molecular diagnostic tests (Photo courtesy of Cepheid).
Image: The Cepheid Xpert Xpress SARS-CoV-2 test was compared favorably with other molecular diagnostic tests (Photo courtesy of Cepheid).
The explosion of COVID-19 cases in the USA has highlighted the critical role diagnostic testing plays in medical and public health decision making in containing and mitigating the SARS-CoV-2 pandemic.

Reverse transcription polymerase chain reaction (RT-PCR) is the mainstay of SARS-CoV-2 detection in vitro. The authorized assays for SARS-CoV-2 have mostly targeted two loci of the coronavirus. Conducting head-to-head evaluations of technologies is one of the best ways to know how well tests work. In a crisis, though, these evaluations must sometimes take a back seat to patient care. Almost four months into the COVID-19 outbreak, test comparisons are now popping up at a rapid pace and positive sense, single-stranded RNA virus by real time RT-PCR and are reported qualitatively.

Medical Laboratory Scientists at the University of Washington Medical Center (Seattle, WA, USA) collected 169 nasopharyngeal (NP) swabs from patient specimens submitted to the University of Washington Medical Center laboratories for clinical diagnostic testing. The team compared the analytical performance of a laboratory developed test (LDT) developed in their clinical laboratory based on CDC primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2. These were: the Xpert Xpress SARS-CoV-2, (Cepheid, Sunnyvale, CA, USA); the Simplexa COVID-19 Direct Kit (DiaSorin Molecular, Cypress, CA, USA); the Panther Fusion SARS-CoV-2 test (Hologic, Bedford, MA, USA); and the cobas SARS-CoV-2 Test (Roche Diagnostics, Risch-Rotkreuz, Switzerland).

The scientists reported that the LDT and Cepheid Xpert Xpress SARS-CoV-2 assays were the most sensitive assays for SARS-CoV-2 with 100% agreement across specimens. The Hologic Panther Fusion, DiaSorin Simplexa, and Roche Cobas 6800 only failed to detect positive specimens near the limit of detection of the CDC-based LDT assay. The in-house LDT demonstrated 100% concordance with the Cepheid Xpert Xpress, also detecting the extremely low viral load specimen as an inconclusive.

The authors concluded that all the assays were 100% specific, using the CDC-based LDT as the gold standard. The results provided initial test performance characteristics for SARS-CoV-2 RT-PCR and highlight the importance of having multiple viral detection testing platforms available in a public health emergency. The study was published on April 29, 2020 in the Journal of Clinical Microbiology.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.